Home » Authors » Rainer B. Langen

Articles by Rainer B. Langen

Schering To Purchase Collateral For $140M In Stock Exchange

March 27, 2002

By Rainer B. Langen

Paion, Millennium Cooperate In Development Of MLN519

March 20, 2002

By Rainer B. Langen

Co.don Starts Phase III Trials Of DISC In Herniated Discs

March 20, 2002

By Rainer B. Langen

LION Streamlining Operations, Eliminating About 80 Positions

Feb. 20, 2002

By Rainer B. Langen

German Officials Compromise In Embryonic Stem Cell Debate

Feb. 6, 2002

By Rainer B. Langen

BioVisioN Raises EUR15M To Progress Programs In Peptides

Feb. 6, 2002

By Rainer B. Langen

Biogen Paying Schering $20M Or More Over MS Drug Patents

Jan. 30, 2002

By Rainer B. Langen

Merck KGaA Says Development Of ImClone Drug Stays On Track

Jan. 25, 2002

By Rainer B. Langen

Estonia Expects Gene Project To Help Health, Economy; Latvia Next

Jan. 23, 2002

By Rainer B. Langen

LION Acquiring NetGenics In Stock Deal Valued At US$17M

Jan. 23, 2002

By Rainer B. Langen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....